Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART

European Journal of Clinical Pharmacology

Volumn 63, Issue 11, 2007, Pages 1019-1029

  Panhard, Xavière ^a,b,c   Legrand, Mayeule ^d   Taburet, Anne Marie ^e   Diquet, Bertrand ^f   Goujard, Cécile ^e   Mentré, France ^a,b,c   Calvez, V ^d   Chene G ^a   Diquet, B ^d   Katlama, C ^d   Leport, C ^b   Metro, A ^g   Peytavin, G ^b   Raffi, F ^h   Roux, A ⁱ   Salmon Ceron, D ^j  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e BICÊTRE HOSPITAL   (France)

^f ANGERS UNIVERSITY HOSPITAL   (France)

^g ANRS   (France)

^h HÔTEL DIEU   (France)

ⁱ HÔPITAL AMBROISE PARÉ   (France)

^j ANRS ^*  (France)

more..

Author keywords

Drug drug interactions; Nucleoside analogs; Population pharmacokinetics

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POPULATION MODEL; PRIORITY JOURNAL;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HUMANS; INDINAVIR; LAMIVUDINE; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NELFINAVIR; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; TISSUE DISTRIBUTION; ZIDOVUDINE;

EID: 35248881543     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0337-x     Document Type: Article

References (28)

1. Stretcher B (1995) Pharmacokinetic optimisation of antiretroviral therapy in patients with HIV infection. Clin Pharmacokinet 29(1):46-65
2. Hoetelmans R, Burger D, Meenhorst P, Beijnen J (1996) Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic- pharmacodynamic relationships. Clin Pharmacokinet 30(4):314-327
3. Fletcher C, Acosta E, Henry K, Page L, Gross C, Kawle S, Remmel R, Erice A, Balfour H (1998) Concentration-controlled zidovudine therapy. Clin Pharmacol Ther 64(3):331-338
4. Kakuda T, Page L, Anderson P, Henry K, Schacker T, Rhame F, Acosta E, Brundage R, Fletcher C (2001) Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob Agents Chemother 45(1):236-242
5. Goujard C, Legrand M, Panhard X, Diquet B, Duval X, Peytavin G, Vincent I, Katlama C, Leport C, Bonnet B, Salmon-Céron D, Mentré F, Taburet A, the COPHAR1 ANRS 102 Study Group (2005) High variability of indinavir and nelfinavir pharmacokinetics in HIV-infected patients with a sustained virological response on haart. Clin Pharmacokinet 44(12):1267-1278
6. Brendel K, Legrand M, Taburet A, Baron G, Goujard C, Mentré F, the Cophar 1-ANRS 102 Trial Group (2005) Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. Fundam Clin Pharmacol 19(3):373-383
7. Panhard X, Goujard C, Legrand M, Taburet A, Diquet B, Mentré F, study group CA (2005) Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART. Br J Clin Pharmacol 60(4):390-403
8. Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti J, the APROCO cohort study group (2002) Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med 54(10):1481-1496
9. Aymard G, Legrand M, Trichereau N, Diquet B (2000) Determination of twelve antiretroviral agents in human plasma sample using reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 744(2):227-240
10. Beal S (2001) Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 28(5):481-504
11. Lindstrom M, Bates D (1990) Nonlinear mixed effects models for repeated measures data. Biometrics 46(3):673-687
12. Pinheiro J, Bates D (2000) Mixed-effect models in S and Splus. Springer-Verlag, New York
13. R Development Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria 2005
14. Akaike H (1973) Statistical predictor identification. Ann Inst Statist Math 22:203-217
15. Gitterman S, Drusano G, Egorin M, Standiford H (1990) Population pharmacokinetics of zidovudine. The Veterans Administration Cooperative Studies Group. Clin Pharmacol Ther 48(2):161-167
16. Mentré F, Escolano S, Diquet B, Golmard J, Mallet A (1993) Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity. Eur J Clin Pharmacol 45(5):397-407
17. Horton C, Dudley M, Kaul S, Mayer K, Squires K, Dunkle L, Anderson R (1995) Population pharmacokinetics of stavudine (d4T) in patients with AIDS or advanced AIDS-related complex. Antimicrob Agents Chemother 39(10):2309-2315
18. Harb G, Mandema J, Delahunty T, Benowitz N, Coleman R, Sheiner L, Jacobson M (1996) Population pharmacokinetics of didanosine in patients with human immunodeficiency virus infection. J Infect Dis 173(1):273
19. Adams J, Shelton M, Hewitt R, DeRemer M, DiFrancesco R, Grasela T, Morse G (1998) Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother 42(2):409-413
20. Moore K, Yuen G, Hussey E, Pakes G, Eron J, Bartlett J (1999) Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials. Antimicrob Agents Chemother 43(12):3025-3029
21. Weller S, Radomski K, Lou Y, Stein D (2000) Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother 44(8):2052-2060
22. Zhou X, Sheiner L, D'Aquila R, Hughes M, Hirsch M, Fischl M, Johnson V, Myers M, Sommadossi J (1999) Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother 43(1):121-128
23. Jullien V, Tréluyer J, Rey E, Jaffray P, Krivine A, Moachon L, Louet ALL, Lescoat A, Dupin N, Salmon D, Pons G, Urien S (2005) Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother 49(8):3361-3366
24. Angel J, Hussey E, Hall S, Donn K, Morris D, McCormack J, Montaner J, Ruedy J (1993) Pharmacokinetics of 3TC (GR109714X) administered with and without food to HIV-infected patients. Drug Invest 6(2):70-74
25. Moore K, Shaw S, Laurent A, Lloyd P, Duncan B, Morris D, O'Mara M, Pakes G (1999) Lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with lamivudine and zidovudine administered concurrently and the effect of food on absorption. J Clin Pharmacol 39(6):593-605
26. Aarnoutse RE, Schapiro JM, Boucher CAB, Hekster YA, Burger DM (2003) Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs? Drugs 63(8):741-753
27. Drusano G, Yuen G, Lambert J, Seidlin M, Dolin R, Valentine F (1992) Relationship between dideoxyinosine exposure, CD4 counts, and p24 antigen levels in human immunodeficiency virus infection. A phase I trial. Ann Intern Med 116(7):562-566
28. Sasomsin P, Mentré F, Diquet B, Simon F, Brun-Vezinet F (2002) Relationship between exposure to zidovudine and decrease of P24 antigenemia in HIV-infected patients in monotherapy. Fundam Clin Pharmacol 16(5):347-352